|
US2007142414A1
|
|
N-substituted pyrrolopyridinones active as kinase inhibitors
|
|
AU2005203326A1
|
|
Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
|
|
TW200526204A
|
|
1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
|
|
IL165456D0
|
|
Pharm
|
|
US2006046993A1
|
|
Crystalline polymorphic form of irinotecan hydrochloride
|
|
MXPA06001556A
|
|
Pyrimidylpyrrole derivatives active as kinase inhibitors.
|
|
US2005043346A1
|
|
Pyridylpyrrole derivatives active as kinase inhibitors
|
|
TW200510719A
|
|
Method for detecting contaminants in pharmaceutical products
|
|
WO2005015166A1
|
|
Method and apparatus for automated swab sample analysis
|
|
US2005032869A1
|
|
Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
EP1622934A2
|
|
Truncated forms of human dbf4, complexes with their interacting partners and methods for identification of inhibitors thereof
|
|
EP1615933A2
|
|
Fused oxabicyclic aminoalcohols as new scaffolds for combinatorial libraries
|
|
WO2004091620A1
|
|
Combined therapy comprising an indolopyrrolocarbazole derivative and irinotecan
|
|
AU2004222527A1
|
|
Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor
|
|
MXPA05009851A
|
|
Nemorubicin as radiosensitizer in combination with radiation therapy against tumors.
|
|
BRPI0408486A
|
|
active bicyclopyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
EP1599210A1
|
|
A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
|
|
TW200427468A
|
|
Semisolid matrix pharmaceutical formulations
|
|
WO2004071507A1
|
|
Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
BRPI0407596A
|
|
semi-solid oral formulations for immediate release comprising a hydrophobic anticancer agent, a polyglycolised glyceride and a hydrophilic carrier
|
